United Therapeutics
UTHR
874 hedge funds and large institutions have $22.6B invested in United Therapeutics in 2026 Q2 according to their latest regulatory filings, with 106 funds opening new positions, 316 increasing their positions, 329 reducing their positions, and 70 closing their positions.
51% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 70
3.37% more ownership
Funds ownership: 94.72% → 98.08% (+3.4%)
2% more funds holding
Funds holding: 853 → 874 (+21)
4% less call options, than puts
Call options by funds: $609M | Put options by funds: $633M
4% less repeat investments, than reductions
Existing positions increased: 316 | Existing positions reduced: 329
8% less capital invested
Capital invested by funds: $24.6B → $22.6B (-$2B)
31% less funds holding in top 10
Funds holding in top 10: 26 → 18 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$203M |
| 2 |
Jane Street
New York
|
+$159M |
| 3 |
Millennium Management
New York
|
+$144M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$105M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$83.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$499M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$158M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$133M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$91.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$76.2M |
UTHR Hedge Fund Activity: Q2 2026 in Review
874 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2026, worth a combined $22.6B — down 8.1% from $24.6B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new UTHR positions and 70 closed out — a net gain of 36 holders — while 316 added to existing stakes and 329 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $203M. The largest seller was Wellington Management Group, cutting an estimated $499M.
- 874 institutional investors held United Therapeutics (UTHR) as of Q2 2026, up from 853 in Q1 2026.
- Funds reported $22.6B of United Therapeutics stock for Q2 2026, down 8.1% quarter-over-quarter.
- 106 funds opened new United Therapeutics positions in Q2 2026 and 70 closed out, a net change of +36 holders.
- The largest United Therapeutics buyer in Q2 2026 was Vestal Point Capital, an estimated $203M added.
- The largest United Therapeutics seller in Q2 2026 was Wellington Management Group, an estimated $499M sold.
Based on aggregated 13F filings for Q2 2026.